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2 
Abstract 
Purpose: Supplementation with dietary forms of vitamin D is commonplace in clinical medicine, elite 
athletic cohorts and the general population, yet the response of all major vitamin D metabolites to high 
doses of vitamin D is poorly characterized. We aimed to identify the responses of all major vitamin D 
metabolites to moderate and high dose supplemental vitamin D3. 
Methods: A repeated measures design was implemented in which 46 elite professional European 
athletes were block randomized based on their basal 25[OH]D concentration into two treatment 
groups. Athletes received either 35,000 or 70,000 IU.week-1 vitamin D3 for 12 weeks and 42 athletes 
completed the trial. Blood samples were collected over 18 weeks to monitor the response to 
supplementation and withdrawal from supplementation. 
Results: Both doses led to significant increases in serum 25[OH]D and 1,25[OH]2D3. 70,000 IU.week-
1 also resulted in a significant increase of the metabolite 24,25[OH]2D at weeks 6 and 12 that persisted 
following supplementation withdrawal at week 18, despite a marked decrease in 1,25[OH]2D3. Intact 
PTH was decreased in both groups by week 6 and remained suppressed throughout the trial. 
Conclusions: High dose vitamin D3 supplementation (70,000 IU.week-1) may be detrimental for its 
intended purposes due to increased 24,25[OH]2D production. Rapid withdrawal from high dose 
supplementation may inhibit the bioactivity of 1,25[OH]2D3 as a consequence of sustained increases in 
24,25[OH]2D that persist as 25[OH]D and 1,25[OH]2D concentrations decrease. These data imply that 
lower doses of vitamin D3 ingested frequently may be most appropriate and gradual withdrawal from 
supplementation as opposed to rapid withdrawal may be favorable.  
 
Key Terms: 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, 1,25-dihydroxyvitamin D3, 
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Text 1 
Introduction 2 
Vitamin D and its metabolites can be described as a group of seco-steroid hormones derived primarily 3 
from dermal synthesis following ultraviolet B (UVB) radiation exposure (sunlight) and also from the 4 
diet. Cholecalciferol (vitamin D3), resulting from both skin exposure to UVB and in limited amounts 5 
from dairy products, oily fish and meat, is considered to be the major contributor to vitamin D 6 
concentration (14); whereas ergocalciferol (vitamin D2) is exclusively derived from the diet of 7 
irradiated plants and mushrooms, and appears to have less biological significance. Following the 8 
photosynthetic conversion of 7-dehydrocholesterol to pre-vitamin D3 and subsequently vitamin D3 (or 9 
cholecalciferol, 14) or following dietary intake, vitamin D is transported in the circulation to the liver 10 
bound to the vitamin D binding protein (DBP), where it is hydroxylated at C-25 by the cytochrome 11 
P450 enzyme CYP27A1 (25-hydroxylase) to form 25-hydroxyvitamin D (25[OH]D or calcidiol). This 12 
metabolite is then carried, again by DBP, to the kidney where at the proximal renal tubule it is 13 
hydroxylated by CYP27B1 (1α-hydroxylase) at C-1α to form the biologically active metabolite, 1,25-14 
dihydroxyvitamin D3 (1,25[OH]2D or calcitriol)(1). The active compound, 1,25[OH]2D has long been 15 
known as a potent modulator of mineral homeostasis via transactivation of genes related to the 16 
maintenance of calcium and phosphate homeostasis. This biological activity is achieved through 17 
interaction of 1,25[OH]2D3 with its receptor, the vitamin D Receptor (VDR), which heterodimerizes 18 
with retinoid X receptor to form a transcriptional complex that can bind to vitamin D response 19 
elements in the promoter of vitamin D regulated genes (12). 20 
 21 
In the past decade, understanding of the biological effects of vitamin D has grown exponentially due 22 
to the development of the vitamin D knockout mouse (22) and high throughput gene microarray 23 
techniques (2). Vitamin D is now understood to be not only an important regulator of mineral 24 
homeostasis but may be influential in cell proliferation and differentiation (21), innate and acquired 25 
immunity (13), muscle development and repair (26, 27) and in the prevention of psychological 26 
diseases such as Alzheimer’s. This is particularly pertinent given the growing understanding that low 27 
vitamin D concentrations (< 30 nmol.L-1) are highly prevalent worldwide in general (34) as well as 28 
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athletic populations (4, 24). Despite a rich research base characterizing the biological importance of 29 
vitamin D, the regulation of the vitamin D endocrine system is less well understood. Practically this is 30 
an important consideration given that some authors advocate high doses of vitamin D, be administered 31 
to individuals with osteomalacia/rickets caused by severe vitamin D deficiency (defined < 12.5 32 
nmol/L), to ameliorate symptoms (15, 19). In the context of professional sport it is commonplace to 33 
supplement entire teams with a blanket approach to vitamin D supplementation, often without basal 34 
concentrations being assessed, and with a target concentration of >100 nmol/L the aim. Perhaps even 35 
more concerning is that the sports teams have access to vitamin D in single capsule form at doses up to 36 
50,000 IU (1,250 µg) making single dose weekly supplementation with mega doses practically very 37 
simple and without definitive guidelines for supplementation this could result in more harm than 38 
benefit. Such practice is in discord with recommendations set by the European Food Safety Authority, 39 
whom advise a safe daily upper limit of 4,000 IU.day-1 (9), in line with advice portrayed by the US 40 
Institute of Medicine (IoM) guidelines for vitamin D intake (33). Notably the US IoM also state a no 41 
adverse effect limit (NOAEL) of 10,000 IU.day-1.  Evidence does not exist to appropriately define the 42 
effect that high dose blanket supplementation protocols, commonly employed in elite sport, have upon 43 
the negative regulators of the vitamin D endocrine system, notably 24,25-hydroxylase (CYP24A1 or 44 
24-hydroxylase), which functions to inactivate both 25[OH]D and 1,25[OH]2D3 (16) by hydroxylation 45 
at C-24. It is important to characterize the response high dose blanket approaches in order to avoid 46 
potentially detrimental effects of too much supplemental vitamin D and contribute toward the 47 
establishment of the most safe and effective vitamin D supplementation schemes for elite athletes. 48 
 49 
The current study therefore aimed to characterize the serum responses of the major vitamin D 50 
metabolites, 25[OH]D, 1,25[OH]2D3, 24,25[OH]2D and iPTH to high dose vitamin D supplementation 51 
(35,000 and 70,000 IU vitamin D3 weekly) in an elite professional team sport cohort. It was 52 
hypothesized that supplementation would dose dependently increase total serum 25[OH]D and the 53 
active metabolite 1,25[OH]2D3 in a concomitant manner but would also increase the production of 54 
24,25[OH]2D. 55 
 56 
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Methods 57 
Participants 58 
Forty-six elite male elite professional team sport athletes volunteered to participate in the current trial 59 
(Age = 26 ± 3 years, height = 1.86 ± 0.6 m, weight 101.5 ± 11 kg, fat mass 11.4 ± 3 %). Participants 60 
underwent a medical screening and provided full informed consent prior to inclusion into the study. 61 
Participants were excluded if they were currently taking vitamin D supplements, using sun beds or 62 
injured at the time of the study. Ethical approval was granted by the ethics committee of Liverpool 63 
John Moores University (Ethics code 12/SPS/047). The recruitment for the study began in November 64 
2012 and testing commenced in the same month. The study was concluded in April 2013. The study 65 
was conducted at latitude 52oN during the winter months in order to limit sunlight exposure.  66 
  67 
Supplementation 68 
Participants were randomly allocated to either 35,000 or 70,000 IU.week-1 supplemental vitamin D3 69 
(Maxi Nutrition, UK), herein referred to as moderate and high, respectively. Randomisation was 70 
achieved with blocking based on baseline serum 25[OH]D and the use of a random number table to 71 
allocate participants into balanced groups. The random allocation sequence was allocated by a 72 
member of the research team and known by the rest of the research team at the point of supplement 73 
administration. The supplemental doses were chosen based on the fact that they represent widely 74 
reported supplement strategies (PubMed literature based search), applied experience of the authors in 75 
both clinical and elite sporting settings and also the NOAEL set by the US IoM. Supplements were 76 
taken orally as a bolus in capsule form on a weekly basis to increase compliance with the protocol, 77 
which was 100% as club staff were present during the weekly distribution of supplementation and 78 
monitored the ingestion of capsules in order to track compliance. Supplementation continued for 12 79 
weeks at which point supplementation was ceased to monitor the response of vitamin D metabolites to 80 
withdrawal. Participants were blinded to the supplement they were receiving. Forty two players 81 
completed the trial whilst four dropped out or were excluded for the following reasons; one player did 82 
not tolerate venipuncture, one player would not comply with the supplementation protocol, two 83 
players used sun beds during the trial. The vitamin D supplements were batch screened by 84 
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chromatography and mass spectrometry for contaminants and confirmation of vitamin D content 85 
stated on the label. Screening was performed in accordance with ISO standard 17025. Sunlight 86 
exposure was minimal during the trial due to the latitude at which the players were based. Participants 87 
travelled for a two-day match fixture to a foreign climate at latitude 43oN, in December during a 88 
period of significant cloud cover. Thus, players were exposed to minimal amounts of sunlight during 89 
the study period although no direct measurement of UV exposure was taken. 90 
 91 
Blood Sampling 92 
Blood samples were drawn prior to supplementation (basal and then at 6, 12 and 18 (withdrawal) 93 
weeks from the start of supplementation. Blood was obtained from the antecubital vein into two serum 94 
separator tubes and two K2EDTA tubes (Becton, Dickinson and Co. Oxford, UK). Samples were then 95 
separated to isolate serum/plasma via centrifugation at 1500 RCF for 15 minutes at 4 oC. 96 
Serum/plasma was extracted and stored at -80 oC until required for analysis. All samples were 97 
collected in the medical room of a professional sports club. 98 
 99 
Analysis of Vitamin D Metabolites and Parathyroid Hormone 100 
Liquid chromatograph tandem mass spectrometry (LC-MS/MS) analysis of 25[OH]D3, 25[OH]D2, 101 
24,25[OH]2D3 and 24,25[OH]2D2 was performed using a Micromass Quattro Ultima Pt mass 102 
spectrometer (Waters Corp., Milford, MA, USA). NIST SRM972a traceable 25[OH]D3 and 25[OH]D2 103 
calibration standards (Chromsystems, München, Germany) and quality controls (UTAK Laboratories, 104 
CA, USA) were purchased commercially, ranged from 0-200 nmol/L. 24,25[OH]2D3 and 105 
24,25[OH]2D2 calibration standards were prepared from certified standards (IsoSciences, King of 106 
Prussia, PA, USA) spiked into human vitamin D depleted serum (BBI Solutions, Cardiff, UK), ranged 107 
from 0-14.8 nmol/L. To 100 L of human serum samples, calibration standards and quality controls, 108 
200 L of pretreatment solution consist of deuterated 25[OH]D3-[2H6] and 24R,25[OH]2D3-[2H6] in 109 
isopropanol:water 50:50 (v/v) was added to displace binding proteins. After mixing, the samples were 110 
loaded onto Supported Liquid Extraction (SLE+) plates (Biotage, Uppsala, Sweden), which were 111 
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eluted with 1.5 mL of n-heptane. The extraction procedure was performed by Extrahera positive 112 
pressure automation system (Biotage). Eluents were dried under nitrogen, followed by reconstitution 113 
with 50 L 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) (Sigma-Aldrich, Dorset, UK). After a 30 114 
minute incubation period at room temperature, 50 L of water was added to stop the reaction. 20 L 115 
of the derivatised extracts were injected into LC-MS/MS. Separation of vitamin D metabolites were 116 
achieved using core-shell C18 2.7m 50  2.1mm (Restek, PA, USA) reversed-phase column. A 117 
gradient elution profile was set up using mobile phase (A) LCMS grade water and (B) methanol 118 
containing 0.2 mM methylamine in 0.1% formic acid. The gradient at the start was 50:50 (v/v) at 119 
column flow rate of 0.4 mL/min, gradually increased to 99% B. 24,25[OH]2D3/D2 and 25[OH]D3/D2 120 
peaks were eluted at 1.39, 1.42, 1.68 and 1.73 minutes respectively (Supplementary Figure 1). 121 
Optimisation of MS/MS conditions were carried out by direct infusion of derivisated standards into 122 
the ion source via a T-connector. The precursor to product ion transitions were based on the molecular 123 
weight of the methylamine adduct of PTAD derived products (Supplementary Table 1). 124 
 125 
Measurements of total 1,25[OH]2D were carried out using a commercially available enzyme 126 
immunoassay kit (IDS, Boldon, UK). Duplicate samples underwent immunoextraction with a 127 
1,25[OH]2D specific solid phase monoclonal antibody and incubated overnight with sheep anti-128 
1,25[OH]2D. 1,25[OH]2D linked biotin was added the next day, followed by horseradish peroxidase 129 
labelled avidin to selectively bind to biotin complex. After a wash step, colour was developed using a 130 
chromogenic substrate (TMB). The absorbance of the stopped reaction mixtures were read in a 131 
microtiter plate spectrophotometer (Multiskan Go, Thermo Scientific, Finland) at wavelength of 450 132 
nm. 133 
 134 
Intact parathyroid hormone in K2EDTA plasma samples were determined by 135 
electrochemiluminescence immunoassay (ECLIA) performed using Roche e601 analyser (Mannheim, 136 
Germany). Two labelled monoclonal antibodies were employed to react with the N-terminal fragment 137 
(1-37) and C-terminal fragment (38-84) of PTH; forming a sandwich complex. The antibody complex 138 
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was magnetically captured and washed to remove unbound substances. A voltage was applied to 139 
induce chemiluminiescent emission which was measured by a photomultiplier. 140 
 141 
Assay validation 142 
Summary of assay characteristics are described in Supplementary Table 2. Linearity of the methods 143 
were evaluated by analysing stock standards made up from reference calibration solutions spiked into 144 
human sera. Standard curve was constructed by plotting the analyte response against the concentration 145 
of their respective standards. A calibration curves were accepted as linear if the weighted linear 146 
regression produced a correlation coefficient (r2) value of >0.999. Intra and inter-assay imprecision of 147 
the methods were assessed by running quality control (QC) materials 10 times within a single run and 148 
separately over a three-month period. Assays were deemed acceptable when the QC results fall within 149 
±2SD from the mean value. Lower limit of quantification (LLoQ) was determined by the lowest 150 
concentration quantifiable with a precision CV of 20% over 12 replicates and minimum peak signal-151 
to-noise ratio of 10:1 (17). Assay recovery was determined by analysing samples containing a fixed 152 
amount of the analyte and calculate the percentage of the measured value against the sum of 153 
endogenous value plus spiking concentration. 154 
  155 
Statistical Analyses 156 
Comparisons of basal total serum 25[OH]D concentration for the two dose groups were made using an 157 
independent t-test. The effects of vitamin D dose and time on all repeated measures variables was 158 
determined using linear mixed modeling. Time (basal, weeks 6, 12 and 18) and dose (moderate and 159 
high) were modeled as fixed effects and participants as a random effect, with time being modeled as a 160 
continuous variable where linear or quadratic responses were observed. The covariance structure that 161 
minimized the Hurvich and Tsai’s criterion (AICC) value was used for the final fitted model for each 162 
metabolite. Where significant main or interaction effects were observed, post hoc pairwise 163 
comparisons were made with Sidak adjusted p-values. All statistical procedures were conducted using 164 
SPSS v22 for Windows (IBM, Armonk, NY, USA), and two-tailed statistical significance was 165 
accepted at the p < 0.05 level. Descriptive statistics are displayed as means ± standard deviation (SD). 166 
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For the calculation of sample size, Minitab software was used. Pilot work from our laboratories during 167 
the winter months suggested that the standard deviation for test–retest serum 25[OH]D concentrations 168 
(taken 6 weeks apart) in young athletes is ∼12 nmol.L-1. To enable the detection of a meaningful 50 169 
nmol.L-1 increase in total serum 25[OH]D concentration  between pre-supplementation and post-170 
supplementation with 80% power; n = 6 participants per group was required. Thus, the recruitment of 171 
an entire squad of 42 players provided a large enough sample size to make valid conclusions from the 172 
derived data. 173 
 174 
Results 175 
Of the 42 participants that were enrolled onto the trial, 40 were tested for all primary outcome 176 
measures. This was due to player commitment to international duty. However, no participants 177 
presented with adverse side effects to supplementation during the trial and thus no participant was 178 
withdrawn. Basal (pre-treatment) total serum 25[OH]D concentrations were 86 ± 20 and 85 ± 10 179 
nmol.L-1 for high and moderate treatment groups, respectively (Figure 1). These concentrations were 180 
not significantly different between groups (t = 0.20, P = 0.84). . 181 
<Figure 1> 182 
Total serum 25[OH]D, displayed a significant interaction effect (F = 4.30, P = 0.008) between dose 183 
and time. Exploration of this interaction identified that both groups showed significantly elevated 184 
25[OH]D concentrations at weeks 6 (moderate = 108 ± 22 and high = 122 ± 25 nmol.L-1) and 12 185 
(moderate = 163 ± 47 and high = 188 ± 66 nmol.L-1). However, upon supplementation withdrawal the 186 
moderate treatment group demonstrated a return to 25[OH]D concentrations comparable with basal by 187 
week 18 (P = 0.178) whereas the high treatment did not (P = 0.007; Figure 2A).  188 
Concentrations of the bioactive metabolite, 1α,25[OH]2D3 demonstrated a significant main effect for 189 
time (F = 6.13, P = 0.001). In the moderate treatment group, peak concentrations occurred at week 6 190 
(141 ± 58 pmol.L-1). However, a delayed response was observed in the high group with peak 191 
1α,25[OH]2D3  levels occurring at week 12 (112 ± 66 pmol.L-1, Figure 2B). Following 192 
supplementation withdrawal, the concentration of 1α,25[OH]2D3  declined significantly in both groups 193 
at week 18 (moderate, 107 ± 32 and high = 104 ± 42 pmol.L-1, P =  0.042) compared with 194 
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concentrations at week 12 and were comparable with basal by this time point (P = 0.332).  195 
 196 
The inactivated metabolite, 24,25[OH]D, showed comparable values between groups at basal 197 
(moderate = 8.3 ± 2.5 and high = 7.1 ± 1.7  nmol.L-1). Both groups showed significant increases in this 198 
metabolite by week 6 (moderate, P = 0.011 and high, P = 0.000) that continued to increase between 199 
weeks 6 and 12. A significant interaction effect was also detected as the high treatment group 200 
displayed markedly higher peak 24,25[OH]D concentrations (17.3 ± 4.5 nmol.L-1) versus moderate 201 
treatment (11.8 ± 1.9 nmol.L-1).  Interestingly, whereas 1α,25[OH]2D3  declined following 202 
supplementation withdrawal, 24,25[OH]D remained significantly elevated at week 18 when compared 203 
with basal values in both treatment groups (moderate, 11.4 ± 2.2 and high, 15.7 ± 4.6 nmol.L-1; P = 204 
0.000 for both groups). 205 
  206 
Intact parathyroid hormone was significantly suppressed in both groups by week 6 (moderate = 2.3 ± 207 
0.8 and high = 1.9 ± 0.4 pmol.L-1 vs basal values in moderate = 3.2 ± 2.3 and high 2.8 ± 1 pmol.L-1) 208 
and remained suppressed throughout the trial and following the withdrawal of supplementation 209 
(moderate = 2.1 ± 0.8 and high 2 ± 0.6 pmol.L-1).  210 
<Figure 2> 211 
Several studies have also examined the ratios of 25[OH]D and 1α,25[OH]2D3 to 24,25[OH]D and it is 212 
evident that additional information can be obtained that is not always obvious when measuring 213 
absolute concentrations (18, 20, 23). In addition, it has been suggested that the ratio of 25[OH]D to 214 
24,25[OH]D is predictive of the 25[OH]D response to supplementation (35) giving important 215 
information that surpasses simply measuring the absolute values for these metabolites. Therefore we 216 
also calculated ratio data for the relationships between 25[OH]D and 1α,25[OH]2D3 to 24,25[OH]D. 217 
The ratio between 25[OH]D and 1α,25[OH]2D3  showed a significant main effect for time (F = 3.39, P 218 
= 0.023) but no group main effect with ratio’s for both supplemental treatments decreasing over the 219 
duration of the study, reaching significance by week 12 (P = 0.039) and increasing toward pre 220 
treatment values at week 18 (Figure 3A). The ratio of 25[OH]D to the inactivated 24,25[OH]D also 221 
showed a main effect for time (F = 14.94, P = 0.000) and the absence of a group main effect. Both 222 
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groups demonstrated a significant lower ratio at week 18 compared to basal (P = 0.000; Figure 3B). 223 
Finally, the ratio of the bioactive 1α,25[OH]2D3  against the inactivated 24,25[OH]D was assessed. A 224 
significant interaction effect was observed as at week 6 the moderate treatment group showed an 225 
increased ratio whilst the high treatment group showed an inverse relationship. However, by week 12 226 
both treatment groups showed a significantly lower ratio of 1α,25[OH]2D3:24,25[OH]D (P = 0.005) 227 
that was maintained at week 18 following supplementation withdrawal (P = 0.003; Figure 3C). 228 
<Figure 3> 229 
 230 
Discussion 231 
The current investigation sought to define the serum responses of the major vitamin D metabolites in a 232 
professional athletic cohort to establish the efficacy of a blanket supplementation approach using two 233 
commonly employed and commercially available doses of vitamin D3.Our main findings demonstrate 234 
that both 35,000 and 70,000 IU.week-1 oral vitamin D3 supplementation significantly elevated total 235 
serum 25[OH]D concentrations. The highest dose led to an initial rapid increase in 1.25[OH]2D but 236 
then a decrease in serum 1,25[OH]2D at week 12 when there was a significant increase of 237 
24,25[OH]2D3 which had also been significantly increased at week 6. Resultantly, these responses led 238 
to a significantly lower ratio of 1,25[OH]2 D to 24,25[OH]2D from week 6 with the higher, 70,000 IU 239 
treatment. Following the withdrawal of supplementation, the concentrations of 25[OH]D and 240 
1α,25[OH]2D return to basal values within 6 weeks. These data imply that high doses of supplemental 241 
vitamin D3 are sufficient to markedly induce the expression of 24-hydroxylase leading to the negative 242 
control of 1,25[OH]2D activity. Finally, we demonstrate that elevating serum 25[OH]D and 243 
1α,25[OH]2D3 suppresses iPTH appearance in circulation. This finding is in agreement with previous 244 
data published by our group (28) and is underpinned by the understanding that DNA binding 245 
sequences exist in the PTH gene (7), permitting suppression of the gene when adequate ligand 246 
(1,25[OH]2D) is available to induce transcriptional suppression by the VDR (31).  247 
 248 
The fact that the concentration of serum 24,25[OH]2D3 did not show a decline along with 1,25[OH]2D 249 
following the withdrawal of supplementation has practical implications. The finding suggests that the 250 
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activity of 24-hydroxylase is sustained following large increases in 1,25[OH]2D and may persist and 251 
decrease both the concentration and subsequent biological activity of 1,25[OH]2D. Evidence is now 252 
emerging that the 24,25[OH]2D metabolite may act at the VDR as a “blocking molecule” binding to 253 
the VDR decreasing 1,25 [OH]2D activity (6). Since 24,25[OH]2D is present in the circulation in 254 
nmol/L concentration compared to pmol/L for 1,25[OH]2D the significantly higher prevailing 255 
24,25[OH]2D concentrations are liable to contribute to a significant decrease in the activity of the 256 
biologically active 1,25[OH]2D. Thus a dual regulation would appear to be present in subjects 257 
receiving high dose vitamin D supplementation preventing possible toxic effects, namely, 1) the 258 
positive stimulation of 24-hydroxylase and 2) the negative control of the vitamin D receptor activity. 259 
This notion is supported by previous mechanistic evidence that has determined the function of 260 
1α,25[OH]2D in regulating 24-hydroxylase activity in vitro. Identification of two VDREs in the 5’ 261 
region of the CYP24A1 promoter demonstrated that 1α,25[OH]2D3 could potently trans-activate the 262 
CYP24A1 gene, inducing a 10 to 100 fold increase in CYP24A1 mRNA to limit the transcription of 263 
1α,25[OH]2D3 responsive genes (25). Moreover, in vitro studies on primary human myoblasts indicate 264 
that the induction of 24-hydroxylase is dose dependent (11), which is in agreement with the serum 265 
response of 24,25[OH]D seen in vivo in the current study.  266 
 267 
These findings may explain reported observations of deterioration in skeletal muscle function, 268 
increased risk of falls and increased fracture risk in individuals supplemented with extreme dose 269 
vitamin D3 to correct for severe vitamin D deficiency. As an example, in a large-scale trial (n = 2256), 270 
women ≥ 70 years old were randomized to either 500,000 IU of vitamin D3 or placebo. The women 271 
randomized to the supplemental vitamin D3 experienced significantly more falls than the placebo 272 
group in the year following dosing of which the falls ratio was greatest in the first month following the 273 
one off 500,000 IU dose (30). Furthermore, in a retrospective observational cohort study, very low (< 274 
10 nmol.L-1) and high (above 140 nmol.-1) concentrations of 25[OH]D showed an increased risk of all 275 
cause mortality indicating not only a lower limit but also an upper limit for serum 25[OH]D (8). This 276 
hypothesis also lends an explanation for the inconsistency in positive outcomes related to 277 
supplemental vitamin D reported by large-scale meta-analyses (5). It is reasonable to suggest that 278 
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mega dose vitamin D supplements are detrimental to vitamin D target tissues by increasing the 279 
production of 24,25[OH]2D, which may act to block the activity of the VDR. It will be necessary to 280 
now perform mechanistic studies that clarify the function of 24,25[OH]2D and to determine whether 281 
high dose supplementation is detrimental to vitamin D signaling through the VDR. 282 
 283 
The current trial also had limitations that are important to consider for the design of future work. 284 
Firstly, although one of our goals was to use a ‘real world’ blanket supplementation approach, we 285 
acknowledge that the same protocol used in other athletic cohorts with different body composition, 286 
genotype and lower basal serum 25[OH]D concentrations may yield different results. Determining the 287 
response of the vitamin D metabolites to a similar protocol as we have used here across wider athletic 288 
cohorts will allow more conclusive recommendations to be made on dosing concentration and 289 
frequency. Indeed, we have previously shown that basal 25[OH]D concentrations vary across athletes 290 
from different professional sports (3). This assumption is also true for female cohorts and as such we 291 
appreciate that our findings cannot be conclusively extended to the female athletic population. 292 
Regarding genotype, genotypic variation in the vitamin D binding protein influences the response to 293 
exogenous vitamin D (10) and little is known of the variation in genes encoding other vitamin D 294 
metabolizing enzymes such as CY24A1 and CYP24B1. We did not perform genotyping and in light of 295 
recent evidence, we fully support genotype-phenotype studies in the context of vitamin D in future. 296 
Combining a genotyping approach with vitamin D metabolite ratio data, the latter as we have 297 
performed in this study, will offer a great advancement in the understanding of how genotype and 298 
supplementation interact and how this can be managed. We also did not measure serum or urinary 299 
calcium concentrations, which are markers of vitamin D toxicity and also regulate the PTH response. 300 
Measuring Ca2+ excretion would add another aspect to our findings, however we do maintain that the 301 
observed increases in 24,25[OH]D are indicative of too much exposure to exogenous vitamin D. 302 
Finally, future work should aim to monitor FGF-23, a bone derived hormone that can function to 303 
lower both 25[OH]D and 1α,25[OH]2D3 by inducing the CYP24 genes (29). FGF-23 may also be a 304 
player in regulating the metabolite response to high dose supplementation and at present its role in 305 
lowering 25[OH]D by promoting 24-hydroxylase expression is still disputed (32). Extending the 306 
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current findings to a broader range of vitamin D concentrations, coupled with intracellular signaling 307 
cascades related to the vitamin D axis will yield the most inferential data, moving towards safer and 308 
more effective vitamin D supplementation practices in athletes. 309 
 310 
Summary and implications for practice 311 
The data presented here are the first to characterize the response of two major metabolites of vitamin 312 
D in response to two high-dose supplementation protocols in healthy professional athletes. The results 313 
demonstrate that a blanket approach of high-dose supplementation with 70,000 IU.week-1 leads not 314 
only to increased 25[OH]D3 and 1,25[OH]2D3 concentrations but also stimulates elevated 315 
concentrations of the vitamin D metabolite 24,25[OH]2D3, which has been previously shown to limit 316 
the transcriptional activity of 1,25[OH]2D3. We demonstrated that this negative regulatory effect 317 
persists following cessation of vitamin D3 supplementation even as 1,25[OH]2D3 concentrations 318 
decrease. There are a number of novel key implications for practice that arise from our current 319 
observations. Firstly, we speculate that ‘high dose’ bolus supplementation with vitamin D3 is likely to 320 
be detrimental to the intended targeted downstream biological functions due to significant increases in 321 
the negative regulatory molecule, 24,25[OH]2D. Weekly doses amounting to more than 5,000 IU.day-1 322 
may need to be reassessed in light of our data. Rapid withdrawal from high dose supplementation may 323 
result in adverse outcomes as the concentration of 24,25[OH]2D3 remains elevated for several weeks 324 
following withdrawal from supplementation despite declines in 1,25[OH]2D3. If moderate to high 325 
doses of vitamin D3 have been administered, a gradual withdrawal from supplementation is advisable. 326 
At present the optimal approach has not been established. Lower doses administered often (daily) may 327 
offer the most potent beneficial biological effects and limit the transactivation of CYP24A1 and 328 
subsequent production of the negative regulatory molecule, 24,25[OH]2D3. Future research must aim 329 
to establish the appropriate dose and frequency of administration to achieve a positive increase in both 330 
25[OH]D3 and 1,25[OH]2D3 whilst limiting the appearance of increased 24,25[OH]2D3 concentrations. 331 
The generation of 24,25 [OH]2D may be an aspect of the body’s defense mechanism to prevent 332 
“toxicity” when administered high doses of vitamin D. We postulate that single “super” doses of 333 
vitamin D3 administered on a weekly basis as is common practice in many professional sporting 334 
  
 
15 
teams, may result in similar rapid transient increases in 1,25[OH]2D3 leading to significant increases in 335 
the negative regulatory metabolite, 24,25[OH]2D3. Further studies will be required to determine if the 336 
relationship we have observed is seen with higher and lower doses of vitamin D. 337 
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Figure Captions 
 
 
Figure 1. Distribution plot of basal serum total 25[OH]D concentrations in participants allocated to 
the 35,000 (moderate) and 70,000 IU.week-1 (high) supplemental treatment groups. No significant 
differences were detected between groups for basal total serum 25[OH]D. Data were normally 
distributed with no significant difference detected between groups. 
 
Figure 2. Serum responses of the major vitamin D metabolites with treatment of either 35,000 
IU.week-1 or 70,000 IU.week-1 vitamin D3 a) 25-hydroxyvitamin D (25[OH]D) b) 1α,25-
dihydroxyvitamin D3 (1α,25[OH]2D3) c) 24,25-hydroxyvitamin D and d) intact parathyroid hormone 
(iPTH). Samples were collected prior to supplementation (basal) and then at weeks 6, 12 and 18 of 
supplementation. At week 12, supplementation was stopped in both groups. * denotes significance for 
both groups compared with basal and # denotes significance for the 70,000 IU.week-1 compared with 
basal. 
 
Figure 3. Relationships between the major vitamin D metabolites, expressed as ratio at all test time 
points. a) ratio of 25-hydroxyvitamin D (25[OH]D) to the biologically active 1α,25-dihydroxyvitamin 
D3 (1α,25[OH]2D3). b) Ratio of 25[OH]D to the inactive metabolite 24,25[OH]D and c) ratio of 
1α,25[OH]2D3 to 24,25[OH]D. * denotes significance for both groups compared with basal. 
 
Supplementary Figure 1. Chromatogram from an extracted sample containing 86 nmol/L of 
25[OH]D3/D2 and 5.3 nmol/L of 24,25[OH]2D3/D2. 
 
 
